Document:

exv10w1

Exhibit 10.1

EXECUTION VERSION

SEALED AIR CORPORATION

$750,000,000

8.125% Senior Notes due 2019

$750,000,000

8.375% Senior Notes due 2021

Purchase Agreement

September 16, 2011

Citigroup Global Markets Inc.

Merrill Lynch, Pierce, Fenner & Smith

          Incorporated

As Representatives of the Initial Purchasers

c/o Citigroup Global Markets Inc.

388 Greenwich Street

New York, New York 10013

Ladies and Gentlemen:

          Sealed Air Corporation, a corporation organized under the laws of Delaware (the “Company”),
proposes to issue and sell to the several parties named in Schedule I hereto (the “Initial
Purchasers”), for whom you (the “Representatives”) are acting as representative, $750,000,000
principal amount of its 8.125% Senior Notes due 2019 (the “2019 Notes”) and $750,000,000 principal
amount of its 8.375% Senior Notes due 2021 (the “2021 Notes” and, together with the 2019 Notes, the
“Notes”). The Notes are to be issued under an indenture (the “Indenture”), to be dated as of the
Closing Date, among the Company, the Guarantors and HSBC Bank USA, N.A., as trustee (the
“Trustee”).

          The Notes will be guaranteed (the “Guarantees” and together with the Notes, the “Securities”)
on a senior unsecured basis by all of the Company’s wholly-owned domestic subsidiaries that
guarantee the Senior Secured Credit Facilities (as defined below) (the “Guarantors”). The use of
the neuter in this Agreement shall include the feminine and masculine wherever appropriate. Certain
terms used herein are defined in Section 24 hereof.

          The sale of the Securities to the Initial Purchasers will be made without registration of the
Securities under the Act in reliance upon exemptions from the registration requirements of the Act.

          In connection with the sale of the Securities, the Company and the Guarantors have prepared a
preliminary offering memorandum, dated September 15, 2011 (as amended or supplemented at the date
thereof, including any and all exhibits thereto, the “Preliminary Memorandum”), and a final
offering memorandum, dated September 16, 2011 (as amended or supplemented at the Execution Time,
including any and all exhibits thereto, the “Final

 

 

Memorandum”). Each of the Preliminary Memorandum and the Final Memorandum sets forth certain
information concerning the Company, the Guarantors and the Securities. Each of the Company, and
the Guarantors hereby confirms it has authorized the use of the Disclosure Package, the Preliminary
Memorandum and the Final Memorandum, and any amendment or supplement thereto, in connection with
the offer and sale of the Securities by the Initial Purchasers.

          On May 31, 2011, the Company and Diversey Holdings, Inc., a corporation organized under the
laws of Delaware, (“Diversey Holdings”) and Solution Acquisition Corp., a wholly-owned subsidiary
of the Company, entered into the Agreement and Plan of Merger (the “Acquisition Agreement”)
pursuant to which the Company agreed to acquire Diversey Holdings, subject to the terms and
conditions therein (the “Acquisition”). In connection with the Acquisition, the Company will enter
into senior secured credit facilities (the “Senior Secured Credit Facilities” and, together with
the documents, agreements or instruments delivered in connection therewith, the “Senior Secured
Credit Facilities Documentation”). The Securities are being issued as part of the financing that
will be used to consummate the Acquisition.

          Concurrent with the consummation of the Acquisition, the Initial Purchasers and each acquired
Guarantor listed on Schedule IV (the “Acquired Guarantors”) hereto shall execute and deliver a
joinder agreement (the “Joinder Agreement”) substantially in the form attached hereto as Exhibit A,
whereby each such Acquired Guarantor will agree to observe and fully perform all of the rights,
obligations and liabilities contemplated herein as if it were an original signatory hereto.

          This Agreement, the Indentures, the Securities, and the Joinder Agreement are referred to
herein as the “Transaction Documents”.

          1. Representations and Warranties. Each of the Company and the Guarantors represents
and warrants to, and agrees with, (in the case of the Acquired Guarantors, upon the execution and
delivery of the Joinder Agreement) each Initial Purchaser that, as of the date hereof and as of the
Closing Date:

          (a) (i) The Disclosure Package did not, as of the Execution Time, contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading, (ii) the
Preliminary Memorandum did not, as of the date thereof, contain and the Final Memorandum, on the
Closing Date (as defined in Section 3), will not contain any untrue statement of a material fact or
omit to state a material fact necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading, and (iii) an electronic road show, if
any, when taken together with the Disclosure Package, does not, and on the Closing Date (as defined
in Section 3), will not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements therein, in the light of the circumstances under which they
were made, not misleading, except that the representations and warranties set forth in this
paragraph do not apply to statements or omissions in the Preliminary Memorandum, the Disclosure
Package or the Final Memorandum based upon information relating to any Initial Purchaser furnished
to the Company in writing by such Initial Purchaser through you expressly for use therein.

2

 

          (b) Except for the Additional Written Offering Communications, if any, identified in Schedule
III hereto, and electronic road shows, if any, furnished to you before first use, the Company and
Guarantors have not prepared, made, used, authorized, approved or distributed and will not prepare,
make, use, authorize, approve or distribute any Additional Written Offering Communication except in
each case used in accordance with Section 5(d).

          (c) Each of the Company and the Guarantors has been duly incorporated or formed, is validly
existing as a corporation, limited liability company, partnership or other legal entity in good
standing under the laws of the jurisdiction of its incorporation or formation, and each has the
corporate, limited liability company, partnership or similar power and authority to own its
property and to conduct its business as described in the Disclosure Package and the Final
Memorandum and is duly qualified to transact business and is in good standing in each jurisdiction
in which the conduct of its business or its ownership or leasing of property requires such
qualification, except to the extent that the failure to be so qualified or be in good standing
would not have a material adverse effect on the Company and the Guarantors and their respective
subsidiaries, taken as a whole.

          (d) Each subsidiary of the Company and the Guarantors has been duly incorporated or formed, is
validly existing as a corporation, limited liability company, partnership or other legal entity in
good standing under the laws of the jurisdiction of its incorporation, has the corporate, limited
liability company, partnership or other similar power and authority to own its property and to
conduct its business as described in the Disclosure Package and the Final Memorandum and is duly
qualified to transact business and is in good standing in each jurisdiction in which the conduct of
its business or its ownership or leasing of property requires such qualification, except to the
extent that the failure to be so qualified or be in good standing would not have a material adverse
effect on the Company and the Guarantors and their respective subsidiaries, taken as a whole.

          (e) All of the issued shares of capital stock of the Company have been duly and validly
authorized and issued, are fully paid and non-assessable and, except as otherwise set forth in the
Disclosure Package and the Final Memorandum or as set forth in Exhibit 21 to the Company’s annual
report on Form 10-K for the year ended December 31, 2010 or in Section 4.2(b) of the Soap
Disclosure Letter to the Acquisition Agreement, all outstanding shares of capital stock of each
subsidiary of the Company are owned by the Company, either directly or through wholly-owned
subsidiaries, free and clear of any security interest, claim, lien or encumbrance.

          (f) Each of the Company and the Guarantors has all requisite corporate or other organizational
power and authority to execute, deliver and perform its obligations under the Transaction Documents
to which they are a party.

          (g) This Agreement has been duly authorized, executed and delivered by each of the Company and
the Guarantors (other than the Acquired Guarantors).

          (h) The Notes have been duly authorized by the Company, and, when executed and authenticated
in accordance with the provisions of the Indenture and delivered to and paid for by the Initial
Purchasers in accordance with the terms of this Agreement, will be

3

 

valid and binding obligations of the Company, enforceable in accordance with their terms,
subject to applicable bankruptcy, insolvency and similar laws affecting creditors’ rights generally
and general principles of equity, and will be entitled to the benefits of the Indenture.

          (i) The Guarantees have been duly authorized by the Guarantors and, when the Notes have been
executed and authenticated in accordance with the provisions of the Indenture and delivered to and
paid for by the Initial Purchasers in accordance with the terms of this Agreement, will be valid
and binding obligations of the Guarantors, enforceable in accordance with their terms, subject to
applicable bankruptcy, insolvency and similar laws affecting creditors’ rights generally and
general principles of equity, and will be entitled to the benefits of the Indenture.

          (j) The Indenture has been duly authorized, and when the Indenture has been executed and
delivered by the Company and the Guarantors, the Indenture will be the valid and binding agreement
of, the Company and the Guarantors, enforceable in accordance with its terms, subject to applicable
bankruptcy, insolvency and similar laws affecting creditors’ rights generally and general
principles of equity.

          (k) On the Closing Date (as defined in Section 3), the Joinder Agreement will be duly
authorized, executed and delivered by the Acquired Guarantors and will be a valid and binding
agreement of such Acquired Guarantors, enforceable in accordance with its terms, subject to
applicable bankruptcy, insolvency and similar laws affecting creditors’ rights generally and
general principles of equity.

          (l) No consent, approval, authorization or order of, or qualification with, any governmental
body or agency is required for the performance by the Company or the Guarantors of their respective
obligations under the Transaction Documents to which they are a party, except such as may be
required by the securities or Blue Sky laws of the various states or other jurisdictions in
connection with the offer and sale of the Securities.

          (m) None of the Company and the Guarantors or any of their respective subsidiaries is in
violation or default of (i) any provision of its charter or by-laws or comparable constituting
documents; (ii) the terms of any indenture, contract, lease, mortgage, deed of trust, note
agreement, loan agreement or other agreement, obligation, condition, covenant or instrument to
which it is a party or bound or to which its property is subject; or (iii) any statute, law, rule,
regulation, judgment, order or decree applicable to the Company and the Guarantors or any of their
respective subsidiaries of any court, regulatory body, administrative agency, governmental body,
arbitrator or other authority having jurisdiction over the Company and the Guarantors or such
subsidiary or any of its properties, as applicable, except, in each case, with respect to items
(ii) and (iii) above, to the extent that such violation or default would not have a material
adverse effect on the Company, the Guarantors or their respective subsidiaries, taken as a whole.

          (n) The execution and delivery by the Company and the Guarantors of, and the performance by
the Company and the Guarantors of its obligations under, the Transaction Documents to which they
are a party, will not conflict with, result in a breach or violation or imposition of, any lien,
charge or encumbrance upon any property or asset of the Company and

4

 

the Guarantors or any of their respective subsidiaries (other than any
imposition of any lien, charge or encumbrance created by the Senior Secured Credit Facilities
Documentation) or contravene any provision of applicable law or the certificate of
incorporation or by-laws or similar organizational documents of the Company and the Guarantors or
any agreement or other instrument binding upon the Company or the Guarantors or any of their
respective subsidiaries, or any judgment, order or decree of any governmental body, agency or court
having jurisdiction over the Company and the Guarantors or any of their respective subsidiaries,
that, in each case, is material to the Company and the Guarantors and their respective subsidiaries
or to which its or their property is subject, taken as a whole.

          (o) (i) The consolidated historical financial statements of the Company and its consolidated
subsidiaries included in the Disclosure Package and the Final Memorandum present fairly the
financial condition, results of operations and cash flows of the Company as of the dates and for
the periods indicated and have been prepared in conformity with generally accepted accounting
principles in the United States (“GAAP”) applied on a consistent basis throughout the periods
involved (except as otherwise noted therein); (ii) the consolidated historical financial
statements of Diversey Holdings and its consolidated subsidiaries included in the Disclosure
Package and the Final Memorandum present fairly the financial condition, results of operations and
cash flows of Diversey Holdings as of the dates and for the periods indicated and have been
prepared in conformity with GAAP applied on a consistent basis throughout the periods involved
(except as otherwise noted therein); (iii) the selected financial data set forth under the captions
“Sealed Air Selected Historical Financial Information” and “Diversey Selected Historical Financial
Information” in the Preliminary Memorandum, Disclosure Package and the Final Memorandum fairly
present, on the basis stated in the Preliminary Memorandum and the Final Memorandum, the
information included therein; (iv) the pro forma condensed combined financial statements included
in the Disclosure Package and the Final Memorandum include assumptions that provide a reasonable
basis for presenting the significant effects directly attributable to the transactions and events
described therein, the related pro forma adjustments give appropriate effect to those assumptions,
the pro forma adjustments reflect the proper application of those adjustments to the historical
financial statement amounts in the pro forma financial statements included in the Disclosure
Package and the Final Memorandum; and, except as otherwise disclosed in the Disclosure Package and
on page (iv) of the Final Memorandum, the pro forma financial statements included in the Disclosure
Package and the Final Memorandum comply as to form in all material respects with the applicable
accounting requirements of Regulation S-X.

          (p) There has not occurred any material adverse change, or any development involving a
prospective material adverse change, in the financial condition, or in the earnings, business or
operations of the Company and the Guarantors and their respective subsidiaries, taken as a whole,
from that set forth in the Disclosure Package and the Final Memorandum.

          (q) There are no legal or governmental proceedings pending or threatened to which the Company
or the Guarantors or any of their respective subsidiaries is a party or to which any of the
properties of the Company or the Guarantors or their subsidiaries is subject other than proceedings
described in all material respects in the Disclosure Package and the Final Memorandum and
proceedings that would not have a material adverse effect on the Company or the Guarantors and any
of their respective subsidiaries, taken as a whole, or on the power or

5

 

ability of the Company or the Guarantors to perform their obligations under this Agreement,
the Indentures or the Securities or to consummate the transactions contemplated by this Agreement.

          (r) The Company, the Guarantors and their respective subsidiaries (i) are in compliance with
any and all applicable foreign, federal, state and local laws and regulations relating to the
protection of human health and safety, the environment or hazardous or toxic substances or wastes,
pollutants or contaminants (“Environmental Laws”), (ii) have received all permits, licenses or
other approvals required of them under applicable Environmental Laws to conduct their respective
businesses and (iii) are in compliance with all terms and conditions of any such permit, license or
approval, except where such noncompliance with Environmental Laws, failure to receive required
permits, licenses or other approvals or failure to comply with the terms and conditions of such
permits, licenses or approvals would not, singly or in the aggregate, have a material adverse
effect on the Company, the Guarantors and their respective subsidiaries, taken as a whole.

          (s) In the ordinary course of its business, the Company and the Guarantors conduct a periodic
review of the effect of Environmental Laws on their respective business, operations and properties
of the Company and its subsidiaries, in the course of which it identifies and evaluates associated
costs and liabilities (including, without limitation, any capital or operating expenditures
required for clean-up, closure of properties or compliance with Environmental Laws or any permit,
license or approval, any related constraints on operating activities and any potential liabilities
to third parties). On the basis of such review and the amount of its established reserves, neither
the Company nor the Guarantors has reasonably concluded that such associated costs and liabilities
would not, individually or in the aggregate, result in a material adverse effect on the Company,
the Guarantors and their respective subsidiaries, taken as a whole.

          (t) Each of the Company, the Guarantors and their respective subsidiaries owns all the
patents, trademarks, permits, service marks, trade names, copyrights, licenses, franchises and
formulas, or rights with respect to the foregoing that are material to the conduct of the Company,
the Guarantors and their respective subsidiaries taken as a whole, or each has obtained licenses or
assignments of all other rights of whatever nature that are material to the conduct of the Company,
the Guarantors and their respective subsidiaries taken as a whole necessary for the present conduct
of its business, without any known conflict with the rights of others which, or, to the Company’s
knowledge, the failure to obtain which, as the case may be, would have a material adverse effect on
the Company, the Guarantors and their respective subsidiaries, taken as a whole.

          (u) Each of the Company and the Guarantors is not, and after giving effect to the offering and
sale of the Securities and the application of the proceeds thereof as described in Disclosure
Package and the Final Memorandum will not be, an “investment company” as such term is defined in
the Investment Company Act.

          (v) None of the Company, the Guarantors or any of their respective affiliates (as defined in
Rule 501(b) of Regulation D under the Act, an “Affiliate”) has directly, or through any agent, (i)
sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of, any security
(as defined in the Act) which is or will be integrated with the sale of the Securities

6

 

in a manner that would require the registration under the Act of the Securities or (ii)
offered, solicited offers to buy or sold the Securities by any form of general solicitation or
general advertising (as those terms are used in Regulation D under the Act) or in any manner
involving a public offering within the meaning of Section 4(2) of the Act, except that no
representation, warranty or agreement is made by the Company in this paragraph with respect to the
Initial Purchasers.

          (w) None of the Company, the Guarantors or their respective Affiliates, or any person acting
on its or their behalf has engaged in any directed selling efforts (within the meaning of
Regulation S) with respect to the Securities; and each of the Company, the Guarantors or their
respective Affiliates and each person acting on its or their behalf has complied with the offering
restrictions requirement of Regulation S, except that no representation, warranty or agreement is
made by the Company in this paragraph with respect to the Initial Purchasers.

          (x) The Securities satisfy the requirements set forth in Rule 144A(d)(3) under the Act.

          (y) KPMG LLP, which expressed its opinion with respect to the financial statements (which term
as used in this Agreement includes the related notes thereto) and supporting schedules filed with
the U.S. Securities and Exchange Commission (the “Commission”) and, except for the supporting
schedules, included in the Disclosure Package and the Final Memorandum are independent registered
public or certified public accountants within the meaning of Regulation S-X, and any non-audit
services provided by KPMG LLP to the Company, have been approved by the Audit Committee of the
Board of Directors of the Company.

          (z) Ernst & Young LLP, which expressed its opinion with respect to the financial statements
(which term as used in this Agreement includes the related notes thereto) and supporting schedules
filed with the Commission and, except for the supporting schedules, included in the Disclosure
Package and the Final Memorandum are independent registered public or certified public accountants
within the meaning of Regulation S-X, and any non-audit services provided by Ernst & Young LLP to
Diversey Holdings, have been approved by the Audit Committee of the Board of Directors of Diversey
Holdings.

          (aa) The Company and its subsidiaries and their respective officers and directors are in
material compliance with the provisions of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley
Act”, which term, as used herein, includes the rules and regulations of the Commission promulgated
thereunder), that are applicable to the Company and Diversey Holdings and their respective
subsidiaries and their respective officers and directors are in compliance with the provisions of
the Sarbanes-Oxley Act that are applicable to Diversey Holdings.

          (bb) Each of the Company and Diversey Holdings and their respective subsidiaries maintains a
system of accounting controls that is in compliance with the Sarbanes-Oxley Act and is sufficient
to provide reasonable assurances that: (i) transactions are executed in accordance with their
respective management’s general or specific authorization; (ii) transactions

7

 

are recorded as necessary to permit preparation of financial statements in conformity with
generally accepted accounting principles and to maintain accountability for assets; (iii) access to
assets is permitted only in accordance with their respective management’s general or specific
authorization; and (iv) the recorded accountability for assets is compared with existing assets at
reasonable intervals and appropriate action is taken with respect to any differences.

          (cc) The operations of the Company, the Guarantors and their respective subsidiaries are and
have been conducted at all times in material compliance with applicable financial recordkeeping and
reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended,
the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder
and any related or similar rules, regulations or guidelines issued, administered or enforced by any
governmental agency (collectively, the “Money Laundering Laws”) and no action, suit or proceeding
by or before any court or governmental agency, authority or body or any arbitrator involving the
Company, the Guarantors or any of their respective subsidiaries with respect to the Money
Laundering Laws is pending or, to the best of the Company’s knowledge, threatened.

          (dd) None of the Company, the Guarantors or any of their respective subsidiaries or, to the
knowledge of the Company, any director, officer, agent, employee or affiliate of the Company, the
Guarantors or any of their respective subsidiaries is currently subject to any U.S. sanctions
administered by the Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”); and
the Company and the Guarantors will not directly or indirectly use the proceeds of the offering, or
lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner
or other person or entity, for the purpose of financing the activities of any person currently
subject to any U.S. sanctions administered by OFAC.

          (ee) None of the Company, the Guarantors or any of their respective subsidiaries or, to the
knowledge of the Company, any director, officer, agent, employee or Affiliate of the Company or the
Guarantors or any of their respective subsidiaries has taken any action, directly or indirectly,
that would result in a current violation by such persons of the Foreign Corrupt Practices Act of
1977, as amended, and the rules and regulations thereunder (the “FCPA”), including, without
limitation, making use of the mails or any means or instrumentality of interstate commerce
corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of
any money, or other property, gift, promise to give, or authorization of the giving of anything of
value to any “foreign official” (as such term is defined in the FCPA) or any foreign political
party or official thereof or any candidate for foreign political office, in contravention of the
FCPA; and the Company, the Guarantors, and their respective subsidiaries and, to the knowledge of
the Company and the Guarantors, their respective Affiliates are conducting their businesses in
compliance with the FCPA and have instituted and maintain policies and procedures designed to
ensure, and which are reasonably expected to continue to ensure, continued compliance therewith.

          (ff) None of the Company or the Guarantors has taken, or will take, directly or indirectly,
any action designed to, or that constitutes or that could reasonably be expected to, cause or
result, under the Exchange Act or otherwise, in any stabilization or manipulation of the price of
the Securities or any security of the Company. None of the Company or the Guarantors

8

 

has issued, or will issue, without the prior consent of the Initial Purchasers, any
stabilization announcement referring to the proposed issue of the Securities.

          (gg) The Company, the Guarantors and their respective subsidiaries have filed all applicable
tax returns that are required to be filed or have requested extensions thereof (except in any case
in which the failure so to file would not have a material adverse effect on the Company, the
Guarantors or their respective subsidiaries, taken as a whole, and except as set forth in or
contemplated in the Disclosure Package and the Final Memorandum) and have paid all taxes required
to be paid by them and any other assessment, fine or penalty levied against them, to the extent
that any of the foregoing is due and payable, except for any such assessment, fine or penalty that
is currently being contested in good faith or is included in balance sheet reserves or as would not
have a material adverse effect on the Company, the Guarantors and their respective subsidiaries,
taken as a whole, and except as set forth in or contemplated in the Disclosure Package and the
Final Memorandum.

          (hh) No labor dispute with the employees of the Company, the Guarantors or any of their
respective subsidiaries exists or, to the Company’s knowledge, is threatened or imminent, and none
of the Company or the Guarantors has knowledge of any existing or imminent labor dispute between
the employees of any of their respective or their respective subsidiaries’ principal suppliers,
contractors or customers and such principal suppliers, contractors or customers, except as would
not have a material adverse effect on the Company, the Guarantors and their respective
subsidiaries, taken as a whole, and except as set forth in or contemplated in the Disclosure
Package and the Final Memorandum.

          (ii) No subsidiary of the Company or the Guarantors is currently, or, immediately following
the Acquisition, will be, prohibited, directly or indirectly, from paying any dividends to the
Company or the Guarantors, as applicable, from making any other distribution the Company or the
Guarantors on such subsidiary’s capital stock, from repaying to the Company or the Guarantors, as
applicable, any loans or advances to such subsidiary from the Company or the Guarantors, as
applicable, or from transferring any of such subsidiary’s property or assets to the Company or the
Guarantors, as applicable, except pursuant to the Senior Secured Credit Facilities Documentation or
the Indentures or as described in or contemplated in the Disclosure Package or the Final
Memorandum.

          (jj) The Company, the Guarantors and each of their respective subsidiaries are insured by
insurers of recognized financial responsibility against such losses and risks and in such amounts
as are prudent and customary in the businesses in which they are engaged; and none of the Company,
the Guarantors, or any of their respective subsidiaries has any reason to believe that it will not
be able to renew its existing insurance coverage as and when such coverage expires or to obtain
similar coverage from similar insurers as may be necessary to continue its business.

Except as would not have a material adverse effect on the Company, the Guarantors and their
respective subsidiaries, taken as a whole: (i) the minimum funding standard under Section 302 of
the Employee Retirement Income Security Act of 1974, as amended, and the applicable regulations
thereunder (“ERISA”), has been satisfied by each “pension plan” (as defined in Section 3(2) of
ERISA) that is subject to Title IV of ERISA (each, a “Plan”) and that has been

9

 

established or maintained by the Company and/or one or more of its subsidiaries; (ii) the trust
forming part of each such Plan which is intended to be qualified under Section 401 of the Code is
so qualified; (iii) each of the Company and its subsidiaries has fulfilled its obligations, if any,
under Section 515 of ERISA; (iv) neither the Company nor any of its subsidiaries maintains or is
required to contribute to a “welfare plan” (as defined in Section 3(1) of ERISA) which provides
retiree or other post-employment welfare benefits or insurance coverage (other than “continuation
coverage” (as defined in Section 602 of ERISA)); (v) each Plan, and each welfare plan established
or maintained by the Company, is in compliance in all material respects with the currently
applicable provisions of ERISA; and (vi) neither the Company nor any of its subsidiaries has
incurred or could reasonably be expected to incur any withdrawal liability under Section 4201 of
ERISA, any liability under Section 4062, 4063, or 4064 of ERISA, or any other liability under Title
IV of ERISA.

          Any certificate signed by any officer of the Company or the Guarantors and delivered to the
Representatives or counsel for the Initial Purchasers in connection with the offering of the
Securities shall be deemed a representation and warranty by the Company or the Guarantors, as
applicable, as to matters covered thereby, to each Initial Purchaser.

          In this Section 1, any reference to any “subsidiary” or “subsidiaries” of the Company shall
include Diversey Holdings and its subsidiaries.

          2. Purchase and Sale. Subject to the terms and conditions and in reliance upon the
representations and warranties herein set forth, the Company agrees to sell to each Initial
Purchaser, and each Initial Purchaser agrees, severally and not jointly, to purchase from the
Company, at a purchase price of 98.25% of the principal amount thereof, plus accrued interest, if
any, the principal amount of Notes set forth opposite such Initial Purchaser’s name in Schedule I
hereto.

          3. Delivery and Payment. Delivery of and payment for the Securities shall be made at
10:00 A.M., New York City time, on October 3, 2011, or at such time on such later date not more
than three Business Days after the foregoing date as the Representatives shall designate, which
date and time may be postponed by agreement between the Representatives and the Company with
respect to the Notes, or as provided in Section 9 hereof (such date and time of delivery and
payment for the Securities being herein called the “Closing Date”). Delivery of the Securities
shall be made to the Representatives for the respective accounts of the several Initial Purchasers
against payment by the several Initial Purchasers through the Representatives of the purchase price
thereof to or upon the order of the Company with respect to the Notes by wire transfer payable in
same-day funds to the account specified by the Company. Delivery of the Securities shall be made
through the facilities of The Depository Trust Company unless the Representatives shall otherwise
instruct.

          4. Offering by Initial Purchasers. (a) Each Initial Purchaser acknowledges that the
Securities have not been and will not be registered under the Act and may not be offered or sold
within the United States or to, or for the account or benefit of, U.S. persons, except pursuant to
an exemption from, or in a transaction not subject to, the registration requirements of the Act.

10

 

          (b) Each Initial Purchaser, severally and not jointly, represents and warrants to and agrees
with each of the Company that:

     (i) it has not offered or sold, and will not offer or sell, any Securities
within the United States or to, or for the account or benefit of, U.S. persons (x)
as part of their distribution at any time or (y) otherwise until 40 days after the
later of the commencement of the offering and the Closing Date except:

	 	(A)	 	to those it reasonably believes
to be “qualified institutional buyers” (as defined in Rule 144A
under the Act) or
	 
	 	(B)	 	in accordance with Rule 903 of
Regulation S;

     (ii) neither it nor any person acting on its behalf has made or will make
offers or sales of the Securities in the United States by means of any form of
general solicitation or general advertising (within the meaning of Regulation D) in
the United States;

     (iii) in connection with each sale pursuant to Section 4(b)(i)(A), it has taken
or will take reasonable steps to ensure that the purchaser of such Securities is
aware that such sale may be made in reliance on Rule 144A;

     (iv) neither it, nor any of its Affiliates nor any person acting on its or
their behalf has engaged or will engage in any directed selling efforts (within the
meaning of Regulation S) with respect to the Securities;

     (v) it is an “accredited investor” (as defined in Rule 501(a) of Regulation D);

     (vi) it has complied and will comply with the offering restrictions requirement
of Regulation S;

     (vii) at or prior to the confirmation of sale of Securities (other than a sale
of Securities pursuant to Section 4(b)(i)(A) of this Agreement), it shall have sent
to each distributor, dealer or person receiving a selling concession, fee or other
remuneration that purchases Securities from it during the distribution compliance
period (within the meaning of Regulation S) a confirmation or notice to
substantially the following effect:

“The Securities covered hereby have not been registered under the U.S.
Securities Act of 1933 (the “Act”) and may not be offered or sold within the
United States or to, or for the account or benefit of, U.S. persons (i) as
part of their distribution at any time or (ii) otherwise until 40 days after
the later of the commencement of the offering and the date of closing of the
offering, except in either case in accordance with Regulation S or Rule 144A
under the Act. [Additional restrictions on the offer and sale of the
Securities are described in the offering memorandum for the

11

 

Securities.] Terms used in this paragraph have the meanings given to them by Regulation
S.”;

     (viii) it has only communicated or caused to be communicated and will only
communicate or cause to be communicated any invitation or inducement to engage in
investment activity (within the meaning of Section 21 of the Financial Services and
Markets Act 2000 (the “FSMA”)) received by it in connection with the issue or sale
of any Securities, in circumstances in which Section 21(1) of the FSMA does not
apply to the Company or the Guarantors;

     (ix) it has complied and will comply with all applicable provisions of the FSMA
with respect to anything done by it in relation to the Securities in, from or
otherwise involving the United Kingdom; and

     (x) in relation to each Member State of the European Economic Area which has
implemented the Prospectus Directive (each, a “Relevant Member State”), with effect
from and including the date on which the Prospectus Directive is implemented in that
Relevant Member State (the “Relevant Implementation Date”), it has not made and will
not make an offer of Securities which are the subject of the offering contemplated
by this Agreement to the public in that Relevant Member State other than:

(A) to any legal entity which is a qualified investor as defined in
the Prospectus Directive;

(B) to fewer than 100 or, if the Relevant Member State has
implemented the relevant provision of the 2010 PD Amending Directive,
150, natural or legal persons (other than qualified investors as
defined in the Prospectus Directive), as permitted under the
Prospectus Directive, subject to obtaining the prior consent of the
relevant Initial Purchaser(s) nominated by the Company for any such
offer; or

(C) in any other circumstances falling within Article 3(2) of the
Prospectus Directive,

provided that no such offer of Securities shall require the Company or any Initial
Purchaser to publish a prospectus pursuant to Article 3 of the Prospectus Directive.

For the purposes of this provision, the expression an “offer of Securities to the
public” in relation to any Securities in any Relevant Member State means the
communication in any form and by any means of sufficient information on the terms of
the offer and the Securities to be offered so as to enable an investor to decide to
purchase or subscribe the Securities, as the same may be varied in that Member State
by any measure implementing the Prospectus Directive in that Member State. The
expression “Prospectus Directive” means Directive 2003/71/EC (and amendments
thereto, including the 2010 PD Amending

12

 

Directive, to the extent implemented in the Relevant Member State), and includes any
relevant implementing measure in the Relevant Member State and the expression “2010
PD Amending Directive” means Directive 2010/73/EU.

          5. Agreements. The Company and each of the Guarantors agrees (in the case of the
Acquired Guarantors, upon the execution and delivery of the Joinder Agreement), jointly and
severally, will agree with each Initial Purchaser that:

          (a) The Company and the Guarantors will furnish to each Initial Purchaser and to counsel for
the Initial Purchasers, without charge, during the period referred to in Section 5(c) below, as
many copies of the Disclosure Package and the Final Memorandum and any amendments and supplements
thereto as they may reasonably request.

          (b) The Company and the Guarantors will prepare a final term sheet, containing solely a
description of final terms of the Securities and the offering thereof, in the form approved by you
and substantially in the form attached as Schedule II hereto.

          (c) The Company and the Guarantors will not amend or supplement the Disclosure Package or the
Final Memorandum without the prior written consent of the Representatives.

          (d) If at any time prior to the earlier of (i) the completion of the sale of the Securities by
the Initial Purchasers (as determined by the Representatives) and (ii) the expiration of twelve
months after the date thereof, any event occurs as a result of which the Disclosure Package or the
Final Memorandum, as then amended or supplemented, would include any untrue statement of a material
fact or omit to state any material fact necessary to make the statements therein, in the light of
the circumstances under which they were made or the circumstances then prevailing, not misleading,
or if it should be necessary to amend or supplement the Disclosure Package or the Final Memorandum
to comply with applicable law, the Company or the Guarantors will promptly (i) notify the
Representatives of any such event; (ii) subject to the requirements of Section 5(c), prepare an
amendment or supplement that will correct such statement or omission or effect such compliance; and
(iii) supply any supplemented or amended Disclosure Package or Final Memorandum to the several
Initial Purchasers and counsel for the Initial Purchasers without charge in such quantities as they
may reasonably request.

          (e) Without the prior written consent of the Representatives, the Company or the Guarantors
has not given and will not give to any prospective purchaser of the Securities any written
information concerning the offering of the Securities other than materials contained in the
Disclosure Package, the Final Memorandum or any other offering materials prepared by or with the
prior written consent of the Representatives.

          (f) The Company and the Guarantors will arrange, if necessary, and upon the request of the
Representatives, for the qualification of the Securities for sale by the Initial Purchasers under
the laws of such jurisdictions as the Representatives may reasonably designate (including certain
provinces of Canada) and will maintain such qualifications in effect so long as required, in the
reasonable determination of the Representatives, for the sale of the Securities; provided
that in no event shall the Company or the Guarantors be obligated to qualify to do

13

 

business in any jurisdiction where it is not now so qualified or to take any action that would
subject it to service of process in suits, other than those arising out of the offering or sale of
the Securities, or to subject itself to taxation in excess of a nominal amount in respect of doing
business, in any jurisdiction where it is not now so subject. The Company and the Guarantors will
promptly advise the Representatives of the receipt by them of any notification with respect to the
suspension of the qualification of the Securities for sale in any jurisdiction or the initiation or
threatening of any proceeding for such purpose.

          (g) During the period of one year after the Closing Date, the Company will not, and will not
permit any of its affiliates (as defined in Rule 144 under the Act) to resell any of the Securities
which constitute “restricted securities” under Rule 144 that have been reacquired by any of them,
except in a transaction registered under the Act or in a transaction exempt from registration
thereunder.

          (h) The Company or its subsidiaries, or any person acting on its or their behalf will,
directly or indirectly, make offers or sales of any security, or solicit offers to buy any
security, under circumstances that would require the registration of the Securities under the Act.

          (i) The Company or its subsidiaries, or any person acting on its or their behalf will engage
in any directed selling efforts (within the meaning of Regulation S) with respect to the
Securities; and each of them will comply with the offering restrictions requirement of Regulation
S.

          (j) The Company or its subsidiaries, or any person acting on its or their behalf will engage
in any form of general solicitation or general advertising (within the meaning of Regulation D) in
connection with any offer or sale of the Securities in the United States.

          (k) For so long as any of the Securities are outstanding and are “restricted securities”
within the meaning of Rule 144(a)(3) under the Act, the Company, during any period in which it is
not subject to and in compliance with Section 13 or 15(d) of the Exchange Act, will provide to each
holder of such restricted securities and to each prospective purchaser (as designated by such
holder) of such restricted securities, upon the request of such holder or prospective purchaser,
any information required to be provided by Rule 144A(d)(4) under the Act.

          (l) The Company will cooperate with the Representatives and use its reasonable best efforts to
permit the Securities to be eligible for clearance and settlement through The Depository Trust
Company.

          (m) Each of the Notes will bear, to the extent applicable, the legend contained in “Transfer
Restrictions” in the Preliminary Memorandum and the Final Memorandum for the time period and upon
the other terms stated therein.

          (n) The Company will not for a period beginning on and continuing to and including the
30th day following the Execution Time, without the prior written consent of Citigroup or
Merrill Lynch, Pierce, Fenner & Smith Incorporated, offer, sell, contract to sell, pledge,
otherwise dispose of, or enter into any transaction which is designed to, or might reasonably be
expected to, result in the disposition (whether by actual disposition or effective

14

 

economic disposition due to cash settlement or otherwise) by the Company or any subsidiary of
the Company, directly or indirectly, or announce the offering, of any debt securities issued or
guaranteed by the Company (other than the Securities).

          (o) Neither the Company nor the Guarantors has taken, or will take, directly or indirectly,
any action designed to, or that constitutes or that could reasonably be expected to, cause or
result, under the Exchange Act or otherwise, in any stabilization or manipulation of the price of
the Securities or any security of the Company. None of the Company or the Guarantors has issued,
or will issue, without the prior consent of the Initial Purchasers, any stabilization announcement
referring to the proposed issue of the Securities.

          (p) If not filed electronically with the Commission through the Commission’s Electronic Data
Gathering, Analysis, and Retrieval System (or any successor system), the Company will, for a period
of twelve months following the Execution Time, furnish to the Representatives all reports or other
communications (financial or other) generally made available to its shareholders, and deliver such
reports and communications to the Representatives as soon as they are available.

          (q) The Company shall apply the net proceeds from the sale of the Securities sold by it in the
manner described under the caption “Use of Proceeds” in the Disclosure Package and the Final
Memorandum.

          (r) The Company agrees to pay the costs and expenses relating to the following matters: (i)
the preparation of the Indentures and the issuance of the Securities and the fees of the Trustee;
(ii) the preparation, printing (or reproduction) and delivery (including postage, air freight
charges and charges for counting and packaging) of copies of the Disclosure Package and the Final
Memorandum and each amendment or supplement to either of them as may, in each case, be reasonably
requested for use in connection with the offering and sale of the Securities; (iii) any stamp or
transfer taxes in connection with the original issuance and sale of the Securities; (iv) the
printing (or reproduction) and delivery of this Agreement, any Blue Sky memorandum and all other
agreements or documents printed (or reproduced) and delivered in connection with the offering of
the Securities; (v) any registration or qualification of the Securities for offer and sale under
the securities or Blue Sky laws of the several states, the provinces of Canada and any other
jurisdictions specified pursuant to Section 5(f) (including filing fees and the reasonable fees and
expenses of counsel for the Initial Purchasers relating to such registration and qualification);
(vi) the transportation and other expenses incurred by or on behalf of Company representatives in
connection with presentations to prospective purchasers of the Securities; (vii) the fees and
expenses of the Company’s accountants and the fees and expenses of counsel (including local and
special counsel) for the Company; and (viii) all other costs and expenses incident to the
performance by the Company of its obligations hereunder; provided that except as provided in clause
(v) above, the Initial Purchasers will pay all of their costs and expenses, including fees and
disbursements of their counsel, transfer taxes payable on the resale of any Securities by them and
any advertising expenses related to any offers they may make.

          6. Conditions to the Obligations of the Initial Purchasers. The obligations of the
Initial Purchasers to purchase the Securities shall be subject to the accuracy of the

15

 

representations and warranties of the Company and the Guarantors contained herein at the
Execution Time and the Closing Date, to the accuracy of the statements of the Company and the
Guarantors made in any certificates pursuant to the provisions hereof, to the performance by the
Company and the Guarantors of its obligations hereunder and to the following additional conditions:

          (a) The Company and the Guarantors shall have requested and caused Simpson Thacher & Bartlett
LLP, counsel for the Company, to furnish to the Representatives its opinion and letter, dated the
Closing Date and addressed to the Representatives, to the effect set forth in Exhibit B-1 and
Exhibit B-2.

          (b) The Initial Purchasers shall have received on the Closing Date an opinion of Katherine
White, Vice President, General Counsel and Secretary of the Company, dated the Closing Date, to the
effect set forth in Exhibit C. Such opinion shall be rendered to the Initial Purchasers at the
request of the Company and shall so state therein.

          (c) The Initial Purchasers shall have received on the Closing Date an opinion of Scott
Russell, General Counsel of Diversey Holdings, dated the Closing Date, to the effect set forth in
Exhibit D. Such opinion shall be rendered to the Initial Purchasers at the request of the Company
and shall so state therein.

          (d) The Representatives shall have received from Shearman & Sterling LLP, counsel for the
Initial Purchasers, its opinion and letter, dated the Closing Date and addressed to the
Representatives, the Company and the Guarantors shall have furnished to such counsel such documents
as they request for the purpose of enabling them to pass upon such matters.

          (e) The Representatives shall have received the written opinion of: Kolesar & Leatham, Chtd.,
Nevada counsel for the Company and the Guarantors and Reinhart Boemer Van Deuren, Wisconsin counsel
for the Company and the Guarantors, with respect to such matters as may be reasonably requested by
the Initial Purchasers.

          (f) The Company shall have furnished to the Representatives a certificate, signed by a
principal financial or accounting officer of the Company, on behalf of the Company and not in his
or her individual capacity, dated the Closing Date, to the effect that the signer of such
certificate have carefully examined the Disclosure Package and the Final Memorandum and any
supplements or amendments thereto, and this Agreement and that:

     (i) the representations and warranties of the Company in this Agreement are
true and correct in all material respects (except to the extent already qualified by
materiality, in which case such representations and warranties are true and correct
in all respects) on and as of the Closing Date with the same effect as if made on
the Closing Date, and the Company have complied with all the agreements and
satisfied all the conditions on their part to be performed or satisfied hereunder at
or prior to the Closing Date; and

     (ii) since the date of the most recent financial statements included or
incorporated by reference in the Disclosure Package and the Final Memorandum, there
has been no material adverse change in the condition (financial or

16

 

otherwise), earnings, business or properties of the Company, as applicable, and
their respective subsidiaries, taken as a whole, whether or not arising from
transactions in the ordinary course of business, except as set forth in or
contemplated in the Disclosure Package and the Final Memorandum.

          (g) On the date hereof, the Initial Purchasers shall have received from each of KMPG LLP, the
independent registered public accounting firm for the Company, and Ernst & Young LLP, the
independent registered public accounting firm for Diversey Holdings, a “comfort letter” dated the
date hereof addressed to the Initial Purchasers, in form and substance satisfactory to the
Representatives, covering the relevant financial information in the Disclosure Package and other
customary matters. In addition, on the Closing Date, the Initial Purchasers shall have received
from each such accountants a “bring-down comfort letter” dated the Closing Date addressed to the
Initial Purchasers, in form and substance satisfactory to the Representatives, in the form of the
“comfort letter” delivered on the date hereof, except that (i) it shall cover the relevant
financial information in the Final Memorandum and any amendment or supplement thereto and (ii)
procedures shall be brought down to a date no more than 3 days prior to the Closing Date.

          (h) Subsequent to the Execution Time or, if earlier, the dates as of which information is
given in the Disclosure Package (exclusive of any amendment or supplement thereto) and the Final
Memorandum (exclusive of any amendment or supplement thereto), there shall not have been (i) any
change or decrease specified in the letter or letters referred to in paragraph (f) of this Section
6; or (ii) any change, or any development involving a prospective change, in or affecting the
condition (financial or otherwise), earnings, business or properties of the Company and its
subsidiaries taken as a whole, whether or not arising from transactions in the ordinary course of
business, except as set forth in or contemplated in the Disclosure Package and the Final Memorandum
(exclusive of any amendment or supplement thereto), the effect of which, in any case referred to in
clause (i) or (ii) above, is, in the sole judgment of the Representatives, so material and adverse
as to make it impractical or inadvisable to proceed with the offering or delivery of the Securities
as contemplated in the Disclosure Package and the Final Memorandum (exclusive of any amendment or
supplement thereto).

          (i) On or before the Closing Date, the Company shall have executed the Senior Secured Credit
Facilities Documentation in the form described in the Disclosure Package or the Final Memorandum
and all of the conditions to the borrowing thereunder shall have been satisfied or waived in
accordance with its terms.

          (j) The Securities shall be eligible for clearance and settlement through The Depository Trust
Company, in the case of the Notes.

          (k) Prior to or concurrently with the closing of the offering of the Securities pursuant to
this Agreement, the Senior Secured Credit Facilities Documentation shall have been entered into and
the Company shall have received the funds from borrowings thereunder, and all conditions precedent
to the consummation of the transactions contemplated by the Acquisition Agreement shall have been
satisfied or properly waived and the Acquisition shall have been consummated pursuant to the terms
of the Acquisition Agreement and Diversey Holdings and its subsidiaries shall have become
subsidiaries of the Company.

17

 

          (l) Except for the ratings actions described under the caption “Sealed Air Pro Forma Liquidity and
Capital Resources — Liquidity and Capital Resources—Pro Forma — Debt Ratings” in each of the
Disclosure Package and Final Memorandum, subsequent to the Execution Time, there shall not have
been any decrease in the rating of any of the Company’s or any of the Guarantors’ debt securities
by any “nationally recognized statistical rating organization” (as defined under the Exchange Act)
or any notice given of any intended or potential decrease in any such rating or of a possible
change in any such rating that does not indicate the direction of the possible change.

          If any of the conditions specified in this Section 6 shall not have been fulfilled when and as
provided in this Agreement or waived, or if any of the opinions and certificates mentioned above or
elsewhere in this Agreement shall not be reasonably satisfactory in form and substance to the
Representatives and counsel for the Initial Purchasers, this Agreement and all obligations of the
Initial Purchasers hereunder may be cancelled at, or at any time prior to, the Closing Date by the
Representatives. Notice of such cancellation shall be given to the Company in writing or by
telephone or facsimile confirmed in writing.

          The documents required to be delivered by this Section 6 will be delivered at the office of
counsel for the Initial Purchasers, at 599 Lexington Avenue, New York, NY 10022, or such other
place as agreed among the Company and the Representatives on the Closing Date.

          7. Reimbursement of Expenses. If the sale of the Securities provided for herein is
not consummated because any condition to the obligations of the Initial Purchasers set forth in
Section 6 hereof is not satisfied, because of any termination pursuant to Section 10 hereof or
because of any refusal, inability or failure on the part of the Company or the Guarantors to
perform any agreement herein or comply with any provision hereof other than by reason of a default
by any of the Initial Purchasers, the Company or the Guarantors will reimburse the Initial
Purchasers severally through Citigroup on demand for all expenses (including reasonable fees and
disbursements of counsel) that shall have been reasonably incurred by them in connection with the
proposed purchase and sale of the Securities.

          8. Indemnification and Contribution. (a) Each of the Company and the Guarantors, (in
the case of the Acquired Guarantors, upon the execution and delivery of the Joinder Agreement),
jointly and severally, agrees to indemnify and hold harmless each Initial Purchaser, the directors,
officers, employees, Affiliates and selling agents of each Initial Purchaser and each person who
controls any Initial Purchaser within the meaning of either the Act or the Exchange Act against any
and all losses, claims, damages or liabilities, joint or several, to which they or any of them may
become subject under the Act, the Exchange Act or other U.S. federal or state statutory law or
regulation, at common law or otherwise, insofar as such losses, claims, damages or liabilities or
actions in respect thereof arise out of or are based upon any untrue statement or alleged untrue
statement of a material fact contained in the Disclosure Package, the Final Memorandum, and any
Additional Written Offering Communications or any other written information (including electronic
road shows, if any) used by or on behalf of the Company or the Guarantors in connection with the
offer or sale of the Securities, or in any amendment or supplement thereto, or arise out of or are
based upon the omission or alleged omission to state therein a material fact required to be stated
therein or necessary to make the statements therein, in the light of the circumstances under which
they were

18

 

made, not misleading, and agrees to reimburse each such indemnified party, as incurred, for
any legal or other expenses reasonably incurred by it in connection with investigating or defending
any such loss, claim, damage, liability or action; provided, however, that the
Company and the Guarantors will not be liable in any such case to the extent that any such loss,
claim, damage or liability arises out of or is based upon any such untrue statement or alleged
untrue statement or omission or alleged omission made in the Preliminary Memorandum or the Final
Memorandum, or in any amendment thereof or supplement thereto, in reliance upon and in conformity
with written information furnished to the Company by or on behalf of any Initial Purchaser through
the Representatives specifically for inclusion therein. This indemnity agreement will be in
addition to any liability that the Company or the Guarantors may otherwise have.

          (b) Each Initial Purchaser severally, and not jointly, agrees to indemnify and hold harmless
the Company, the Guarantors, and, in the case of the Acquired Guarantors, upon the execution and
delivery of the Joinder Agreement, each of their respective directors, each of their respective
officers, and each person who controls the Company and the Guarantors within the meaning of either
the Act or the Exchange Act, to the same extent as the foregoing indemnity to each Initial
Purchaser, but only with reference to written information relating to such Initial Purchaser
furnished to the Company by or on behalf of such Initial Purchaser through the Representatives
specifically for inclusion in the Preliminary Memorandum or the Final Memorandum (or in any
amendment or supplement thereto). This indemnity agreement will be in addition to any liability
that any Initial Purchaser may otherwise have. The Company and the Guarantors acknowledge that (i)
the statements set forth in the last paragraph of the cover page regarding delivery of the Notes
and (ii), under the heading “Plan of Distribution”, the last sentence of the 3rd
paragraph, the fourth and fifth sentences of the 7th paragraph, the 8th
paragraph, the 9th paragraph and the 10th paragraph in the Preliminary
Memorandum and the Final Memorandum relating to the purchase and sale of the Notes and
stabilization by the Initial Purchasers constitute the only information furnished in writing by or
on behalf of the Initial Purchasers for inclusion in the Preliminary Memorandum or the Final
Memorandum or in any amendment or supplement thereto.

          (c) Promptly after receipt by an indemnified party under this Section 8 of notice of the
commencement of any action, such indemnified party will, if a claim in respect thereof is to be
made against the indemnifying party under this Section 8, notify the indemnifying party in writing
of the commencement thereof; but the failure so to notify the indemnifying party (i) will not
relieve it from liability under paragraph (a) or (b) above unless and to the extent it did not
otherwise learn of such action and such failure results in the forfeiture by the indemnifying party
of substantial rights and defenses and (ii) will not, in any event, relieve the indemnifying party
from any obligations to any indemnified party other than the indemnification obligation provided in
paragraph (a) or (b) above. The indemnifying party shall be entitled to appoint counsel (including
local counsel) of the indemnifying party’s choice at the indemnifying party’s expense to represent
the indemnified party in any action for which indemnification is sought (in which case the
indemnifying party shall not thereafter be responsible for the fees and expenses of any separate
counsel, other than local counsel if not appointed by the indemnifying party, retained by the
indemnified party or parties except as set forth below); provided, however, that
such counsel shall be satisfactory to the indemnified party. Notwithstanding the indemnifying
party’s election to appoint counsel (including local counsel) to represent the indemnified party in
an action, the indemnified party shall have the right to employ separate counsel (including local
counsel), and

19

 

the indemnifying party shall bear the reasonable fees, costs and expenses of such separate
counsel if (i) the use of counsel chosen by the indemnifying party to represent the indemnified
party would present such counsel with a conflict of interest; (ii) the actual or potential
defendants in, or targets of, any such action include both the indemnified party and the
indemnifying party and the indemnified party shall have reasonably concluded that there may be
legal defenses available to it and/or other indemnified parties that are different from or
additional to those available to the indemnifying party; (iii) the indemnifying party shall not
have employed counsel satisfactory to the indemnified party to represent the indemnified party
within a reasonable time after notice of the institution of such action; or (iv) the indemnifying
party shall authorize the indemnified party to employ separate counsel at the expense of the
indemnifying party. An indemnifying party will not, without the prior written consent of the
indemnified parties, settle or compromise or consent to the entry of any judgment with respect to
any pending or threatened claim, action, suit or proceeding in respect of which indemnification or
contribution may be sought hereunder (whether or not the indemnified parties are actual or
potential parties to such claim or action) unless such settlement, compromise or consent includes
an unconditional release of each indemnified party from all liability arising out of such claim,
action, suit or proceeding.

          (d) In the event that the indemnity provided in paragraph (a) or (b) of this Section 8 is
unavailable to or insufficient to hold harmless an indemnified party for any reason, the Company,
the Guarantors and the Initial Purchasers, severally agree to contribute to the aggregate losses,
claims, damages and liabilities (including legal or other expenses reasonably incurred in
connection with investigating or defending any loss, claim, damage, liability or action)
(collectively “Losses”) to which the Company, the Guarantors and one or more of the Initial
Purchasers may be subject in such proportion as is appropriate to reflect the relative benefits
received by the Company and the Guarantors on the one hand and by the Initial Purchasers, on the
other hand, from the offering of the Securities; provided, however, that in no case
shall any Initial Purchaser be responsible for any amount in excess of the purchase discount or
commission applicable to the Securities purchased by such Initial Purchaser hereunder. If the
allocation provided by the immediately preceding sentence is unavailable for any reason, the
Company, the Guarantors and the Initial Purchasers severally shall contribute in such proportion as
is appropriate to reflect not only such relative benefits but also the relative fault of the
Company and the Guarantors on the one hand and the Initial Purchasers on the other in connection
with the statements or omissions that resulted in such Losses, as well as any other relevant
equitable considerations. Benefits received by the Company and the Guarantors shall be deemed to
be equal to the total net proceeds from the offering (before deducting expenses) received by them,
and benefits received by the Initial Purchasers shall be deemed to be equal to the total purchase
discounts and commissions. Relative fault shall be determined by reference to, among other things,
whether any untrue or alleged untrue statement of a material fact or the omission or alleged
omission to state a material fact relates to information provided by the Company and the Guarantors
on the one hand or the Initial Purchasers on the other, the intent of the parties and their
relative knowledge, access to information and opportunity to correct or prevent such untrue
statement or omission. The Company, the Guarantors and the Initial Purchasers agree that it would
not be just and equitable if contribution were determined by pro rata allocation or any other
method of allocation that does not take account of the equitable considerations referred to above.
Notwithstanding the provisions of this paragraph (d), no person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Act) shall be entitled to
contribution from any person who was not guilty of such fraudulent

20

 

misrepresentation. For purposes of this Section 8, each person who controls an Initial
Purchaser within the meaning of either the Act or the Exchange Act and each director, officer,
employee, Affiliate and selling agent of an Initial Purchaser shall have the same rights to
contribution as such Initial Purchaser, and each person who controls the Company or the Guarantors
within the meaning of either the Act or the Exchange Act and each officer and director of the
Company or the Guarantors shall have the same rights to contribution as the Company or the
Guarantors, respectively, subject in each case to the applicable terms and conditions of this
paragraph (d).

          9. Default by an Initial Purchaser. If any one or more Initial Purchasers shall fail
to purchase and pay for any of the Notes agreed to be purchased by such Initial Purchaser hereunder
and such failure to purchase shall constitute a default in the performance of its or their
obligations under this Agreement, the remaining Initial Purchasers with respect to the Notes shall
be obligated severally to take up and pay for (in the respective proportions which the principal
amount of Notes set forth opposite their names in Schedule I hereto bears to the aggregate
principal amount of Notes set forth opposite the names of all the remaining Initial Purchasers) the
Notes which the defaulting Initial Purchaser or Initial Purchasers agreed but failed to purchase;
provided, however, that in the event that the aggregate principal amount of Notes,
which the defaulting Initial Purchaser or Initial Purchasers agreed but failed to purchase shall
exceed 10% of the aggregate principal amount of Notes set forth in Schedule I hereto, the remaining
Initial Purchasers shall have the right to purchase all, but shall not be under any obligation to
purchase any, of such Notes and if such non-defaulting Initial Purchasers do not purchase all the
Securities, this Agreement will terminate without liability to any non-defaulting Initial Purchaser
or the Company. In the event of a default by any Initial Purchaser as set forth in this Section 9,
the Closing Date shall be postponed for such period, not exceeding five Business Days, as the
Representatives shall determine in order that the required changes in the Final Memorandum or in
any other documents or arrangements may be effected. Nothing contained in this Agreement shall
relieve any defaulting Initial Purchaser of its liability, if any, to the Company or any
non-defaulting Initial Purchaser for damages occasioned by its default hereunder.

          10. Termination. This Agreement shall be subject to termination in the absolute
discretion of the Representatives, by notice given to the Company, with respect to the Notes prior
to delivery of and payment for the Notes if at any time prior to such time (i) trading in
securities generally on the New York Stock Exchange shall have been suspended or limited or minimum
prices shall have been established on such exchange; (ii) a banking moratorium shall have been
declared either by U.S. federal or New York State authorities; or (iii) there shall have occurred
any outbreak or escalation of hostilities, declaration by the United States of a national emergency
or war or other calamity or crisis the effect of which on financial markets is such as to make it,
in the sole judgment of the Representatives, impractical or inadvisable to proceed with the
offering or delivery of the Securities as contemplated in the Disclosure Package and the Final
Memorandum.

          11. Representations and Indemnities to Survive. The respective agreements,
representations, warranties, indemnities and other statements of the Company and each of the
Guarantors, or their respective officers and of the Initial Purchasers set forth in or made
pursuant to this Agreement will remain in full force and effect, regardless of any investigation
made by or on behalf of the Initial Purchasers or the Company or any of the Guarantors, or any of
the

21

 

indemnified persons referred to in Section 8 hereof, and will survive delivery of and payment
for the Securities. The provisions of Sections 7 and 8 hereof shall survive the termination or
cancellation of this Agreement.

          12. The Acquired Guarantors. On the Closing Date, the Company will cause: (i) the
Acquired Guarantors to become parties to the Joinder Agreement; and (ii) each Acquired Guarantor to
(a) become guarantors under the Indentures, as applicable, and (b) execute a Guarantee.

          13. Notices. All communications hereunder will be in writing and effective only on
receipt, and, if sent to the Representatives, will be mailed, delivered or telefaxed to the
Citigroup General Counsel (fax no.: (212) 816-7912) and confirmed to Citigroup at 388 Greenwich
Street, New York, New York 10013, Attention: General Counsel; or to Merrill Lynch, Pierce, Fenner &
Smith Incorporated Legal Department (fax no.: 212-901-7897) and confirmed to it at 50 Rockfeller
Plaza, New York, New York 10020, Attention: Legal Department; or if sent to the Company or the
Guarantors, will be mailed, delivered or telefaxed to General Counsel (fax no.: (201) 703-4231) and
confirmed to it at 200 Riverfront Boulevard, Elmwood Park, New Jersey 07407, attention of the Legal
Department.

          14. Successors. This Agreement will inure to the benefit of and be binding upon the
parties hereto and their respective successors and the indemnified persons referred to in Section 8
hereof and their respective successors, and no other person will have any right or obligation
hereunder.

          15. Jurisdiction. Each of the Company and each of the Guarantors agrees that any
suit, action or proceeding against the Company or any of the Guarantors brought by any Initial
Purchaser, the directors, officers, employees and selling agents of any Initial Purchaser, or by
any person who controls any Initial Purchaser, arising out of or based upon this Agreement or the
transactions contemplated hereby may be instituted in any State or U.S. federal court in The City
of New York and County of New York, and waives any objection which it may now or hereafter have to
the laying of venue of any such proceeding, and irrevocably submits to the non-exclusive
jurisdiction of such courts in any suit, action or proceeding.

          16. Integration. This Agreement supersedes all prior agreements and understandings
(whether written or oral) between the Company and the Initial Purchasers, or any of them, with
respect to the subject matter hereof.

          17. Applicable Law. This Agreement will be governed by and construed in accordance
with the laws of the State of New York.

          18. Waiver of Jury Trial. The Company and the Guarantors hereby irrevocably waive,
(in the case the Acquired Guarantors, upon the execution and delivery of the Joinder Agreement) to
the fullest extent permitted by applicable law, any and all right to trial by jury in any legal
proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.

          19. No Fiduciary Duty. Each of the Company and the Guarantors hereby acknowledge (in
the case the Acquired Guarantors, upon the execution and delivery of the

22

 

Joinder Agreement) that (a) the purchase and sale of the Securities pursuant to this Agreement
is an arm’s-length commercial transaction between the Company and the Guarantors, on the one hand,
and the Initial Purchasers and any Affiliate through which they may be acting, on the other, (b)
the Initial Purchasers are acting as principal and not as an agent or fiduciary of the Company or
the Guarantors and (c) the engagement of the Initial Purchasers by the Company in connection
with the offering and the process leading up to the offering is as independent
contractors and not in any other capacity. Furthermore, each of the Company and each of the
Guarantors agrees that it is solely responsible for making its own judgments in connection with the
offering (irrespective of whether any of the Initial Purchasers has advised or is currently
advising the Company or any of the Guarantors on related or other matters). Each of the Company and
each of the Guarantors agrees that they will not claim that the Initial Purchasers have rendered
advisory services of any nature or respect, or owe an agency, fiduciary or similar duty to them, in
connection with such transaction or the process leading thereto.

          20. Waiver of Immunity. To the extent that the relevant Guarantors have or hereafter
may acquire any immunity (sovereign or otherwise) from any legal action, suit or proceeding, from
jurisdiction of any court or from set-off or any legal process (whether service or notice,
attachment in aid or otherwise) with respect to itself or any of its property, the relevant
Guarantors hereby irrevocably waives and agrees not to plead or claim such immunity in respect of
its obligations under this Agreement.

          21. Waiver of Tax Confidentiality. Notwithstanding anything herein to the contrary,
purchasers of the Securities (and each employee, representative or other agent of a purchaser) may
disclose to any and all persons, without limitation of any kind, the U.S. tax treatment and U.S.
tax structure of any transaction contemplated herein and all materials of any kind (including
opinions or other tax analyses) that are provided to the purchasers of the Securities relating to
such U.S. tax treatment and U.S tax structure, other than any information for which nondisclosure
is reasonably necessary in order to comply with applicable securities laws.

          22. Counterparts. This Agreement may be signed in one or more counterparts, each of
which shall constitute an original and all of which together shall constitute one and the same
agreement.

          23. Headings. The section headings used herein are for convenience only and shall not
affect the construction hereof.

          24. Definitions. The terms that follow, when used in this Agreement, shall have the
meanings indicated.

          “Act” shall mean the Securities Act of 1933, as amended, and the rules and regulations of the
Commission promulgated thereunder.

          “Additional Written Offering Communication” shall mean any written communication (as defined
in Rule 405 under the Securities Act) that constitutes an offer to sell or a solicitation of an
offer to buy the Securities other than the Preliminary Memorandum, the Disclosure Package or the
Final Memorandum.

23

 

          “Affiliate” shall have the meaning specified in Rule 501(b) of Regulation D.

          “Business Day” shall mean any day other than a Saturday, a Sunday or a legal holiday or a day
on which banking institutions or trust companies are authorized or obligated by law to close in The
City of New York.

          “Citigroup” shall mean Citigroup Global Markets Inc.

          “Code” shall mean the Internal Revenue Code of 1986, as amended.

          “Commission” shall mean the U.S. Securities and Exchange Commission.

          “Disclosure Package” shall mean (i) the Preliminary Memorandum and (ii) the final term sheet
prepared pursuant to Section 5(b) hereto and substantially in the form attached as Schedule II
hereto.

          “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, and the rules and
regulations of the Commission promulgated thereunder.

          “Execution Time” shall mean 4:00 p.m. New York City time on the date of this Agreement.

          “Investment Company Act” shall mean the Investment Company Act of 1940, as amended, and the
rules and regulations of the Commission promulgated thereunder.

          “Regulation D” shall mean Regulation D under the Act.

          “Regulation S” shall mean Regulation S under the Act.

          “Regulation S-X” shall mean Regulation S-X under the Act and the Exchange Act.

          “Trust Indenture Act” shall mean the Trust Indenture Act of 1939, as amended, and the rules
and regulations of the Commission promulgated thereunder.

24

 

          If the foregoing is in accordance with your understanding of our agreement, please sign and
return to us the enclosed duplicate hereof, whereupon this letter and your acceptance shall
represent a binding agreement between each of the Company and the Guarantors, and the several
Initial Purchasers.

	 	 	 	 	 
	 	Very truly yours,

Sealed Air Corporation

 	 
	 	By:  	/s/
H. Katherine White	 
	 	 	Name:  	H. Katherine White	 
	 	 	Title:  	Vice President, General Counsel and Secretary	 

[Signature Page to Purchase Agreement]

 

 

	 	 	 	 	 
	 	CPI Packaging, Inc.

 	 
	 	By:  	/s/ H. Katherine White	 
	 	 	Name:  	H. Katherine White	 
	 	 	Title:  	Vice President and Secretary	 
	 
	 	Cryovac, Inc.

 	 
	 	By:  	/s/ H. Katherine White	 
	 	 	Name:  	H. Katherine White	 
	 	 	Title:  	Vice President, General Counsel and Secretary	 
	 
	 	Cryovac International Holdings Inc.

 	 
	 	By:  	/s/ H. Katherine White	 
	 	 	Name:  	H. Katherine White	 
	 	 	Title:  	Vice President and Secretary	 
	 
	 	Cryovac Leasing Corporation

 	 
	 	By:  	/s/ H. Katherine White	 
	 	 	Name:  	H. Katherine White	 
	 	 	Title:  	Vice President and Secretary	 
	 
	 	Poly Packaging Systems, Inc.

 	 
	 	By:  	/s/ H. Katherine White	 
	 	 	Name:  	H. Katherine White	 
	 	 	Title:  	Vice President and Secretary	 
	 
	 	Polypride, Inc.

 	 
	 	By:  	/s/ H. Katherine White	 
	 	 	Name:  	H. Katherine White	 
	 	 	Title:  	Vice President and Secretary	 
	 
	 	Reflectix, Inc.

 	 
	 	By:  	/s/ H. Katherine White	 
	 	 	Name:  	H. Katherine White	 
	 	 	Title:  	Vice President and Secretary	 
	 
	 	Sealed Air Corporation (US)

 	 
	 	By:  	/s/ H. Katherine White	 
	 	 	Name:  	H. Katherine White	 
	 	 	Title:  	Vice President, General Counsel and Secretary	 
	 

[Signature Page to Purchase Agreement]

 

 

	 	 	 	 	 
	 	Sealed Air LLC

 	 
	 	By:  	/s/
H. Katherine White	 
	 	 	Name:  H. Katherine White	 
	 	 	Title:  Vice President and Secretary	 	 
	 
	 	Sealed Air Finance LLC

 	 
	 	By:  	/s/
H. Katherine White	 
	 	 	Name:  H. Katherine White	 	 
	 	 	Title:  Vice President and Secretary	 	 
	 
	 	Sealed Air Nevada Holdings Limited (fka
 Sealed
Air Japan Limited)

 	 
	 	By:  	/s/ H. Katherine White	 
	 	 	 	 
	 	 	Name:   H. Katherine
White
Title:  Vice President and Secretary	 	 
	 
	 	Shanklin Corporation

 	 
	 	By:  	/s/ H. Katherine White	 
	 	 	 	 
	 	 	Name:  H. Katherine White
Title:  Vice President and Secretary	 	 
	 

[Signature Page to Purchase Agreement]

 

 

The foregoing Agreement is hereby

confirmed and accepted as of the

date first above written.

Citigroup Global Markets Inc.

Merrill Lynch, Pierce, Fenner & Smith

               Incorporated

For themselves and the other several

Initial Purchasers named in

Schedule I to the foregoing Agreement.

Citigroup Global Markets Inc.

	 	 	 	 	 
	 	 	 
	 	By:  	/s/
Stuart G. Dickson	 
	 	 	Name:  	Stuart G. Dickson	 
	 	 	Title:  	Managing Director	 
	 

Merrill Lynch, Pierce, Fenner & Smith

               Incorporated

	 	 	 	 	 
	 	 	 
	 	By:  	/s/
Michelle Koren	 
	 	 	Name:  	Michelle Koren	 
	 	 	Title:  	Vice President	 

[Signature Page to Purchase Agreement]

 

 

SCHEDULE I

	 	 	 	 	 
	 	 	Principal
	 	 	Amount of 2019
	 	 	Notes to be
	Initial Purchasers	 	Purchased
	Citigroup Global Markets Inc.
	 	$	338,000,000	 
	Merrill Lynch, Pierce, Fenner & Smith Incorporated
	 	 	169,000,000	 
	RBS Securities Inc.
	 	 	84,000,000	 
	BNP Paribas Securities Corp.
	 	 	84,000,000	 
	Morgan Stanley & Co. LLC
	 	 	25,000,000	 
	Rabo Securities USA, Inc.
	 	 	25,000,000	 
	Credit Agricole Securities (USA) LLC
	 	 	25,000,000	 
	Total
	 	$	750,000,000	 

	 	 	 	 	 
	 	 	Principal
	 	 	Amount of 2021
	 	 	Notes to be
	Initial Purchasers	 	Purchased
	Citigroup Global Markets Inc.
	 	$	338,000,000	 
	Merrill Lynch, Pierce, Fenner & Smith Incorporated
	 	 	169,000,000	 
	RBS Securities Inc.
	 	 	84,000,000	 
	BNP Paribas Securities Corp.
	 	 	84,000,000	 
	Morgan Stanley & Co. LLC
	 	 	25,000,000	 
	Rabo Securities USA, Inc.
	 	 	25,000,000	 
	Credit Agricole Securities (USA) LLC
	 	 	25,000,000	 
	Total
	 	$	750,000,000	 

Schedule I

 

 

SCHEDULE II

Pricing Term Sheet

Schedule II

 

 

Summary of Terms:

8.125% Senior Notes due 2019

	 	 	 

	Issuer:

	 	Sealed Air Corporation
	 
	 	 
	Issue:

	 	Senior Notes
	 
	 	 
	Maturity:

	 	September 15, 2019
	 
	 	 
	Aggregate Principal Amount:

	 	$750,000,000 
	 
	 	 
	Coupon:

	 	8.125% 
	 
	 	 
	Yield to Maturity:

	 	8.125% 
	 
	 	 
	Spread to Benchmark
Treasury:

	 	605 b.p. vs. TSY 2.125% due 8/21
	 
	 	 
	Interest Payment Dates:

	 	March 15 & September 15, commencing March 15, 2012
	 
	 	 
	Price:

	 	100.000% 
	 
	 	 
	Gross Proceeds to Issuer

(before expenses):

	 	$750,000,000 
	 
	 	 
	Record Dates:

	 	March 1 and September 1
	 
	 	 
	Call Schedule:

	 	100% plus a “make-whole premium” prior to September 15, 2015
	 

	 	September 15, 2015: 104.063%
	 

	 	September 15, 2016: 102.031%
	 

	 	September 15, 2017: 100.000%
	 

	 	and thereafter
	 
	 	 
	Equity Clawback:

	 	35% at 108.125% prior to September 15, 2014
	 
	 	 
	Change of Control:

	 	Investor put at 101%
	 
	 	 
	Make Whole:

	 	T + 50 b.p.
	 
	 	 
	Denominations:

	 	Minimum denominations of $2,000 and integral multiples of
$1,000 in excess thereof
	 
	 	 
	Joint Book-Running Managers:

	 	Citigroup Global Markets Inc.

Merrill Lynch, Pierce, Fenner & Smith Incorporated

Morgan Stanley & Co. LLC

RBS Securities Inc.
	 
	 	 
	Co-Managers:

	 	BNP Paribas Securities Corp.

Credit Agricole Securities (USA) LLC

Rabo Securities USA, Inc.
	 
	 	 
	Trade Date:

	 	September 16, 2011
	 
	 	 
	Settlement Date (T + 11):

	 	October 3, 2011
	 
	 	 
	Registration Rights:

	 	None
	 
	 	 
	Distribution:

	 	144A and Regulation S

1

 

	 	 	 	 	 

	CUSIP/ISIN:

	 	144A Notes:
	 	Reg. S Notes:
	 

	 	CUSIP: 81211K AQ3
	 	CUSIP: U81193 AG6
	 

	 	ISIN: US81211KAQ31
	 	ISIN: USU81193AG69

8.375% Senior Notes due 2021

	 	 	 

	Issuer:

	 	Sealed Air Corporation
	 
	 	 
	Issue:

	 	Senior Notes
	 
	 	 
	Maturity:

	 	September 15, 2021
	 
	 	 
	Aggregate Principal Amount:

	 	$750,000,000 
	 
	 	 
	Coupon:

	 	8.375% 
	 
	 	 
	Yield to Maturity:

	 	8.375% 
	 
	 	 
	Spread to Benchmark
Treasury:

	 	630 b.p. vs. TSY 2.125% due 8/21
	 
	 	 
	Interest Payment Dates:

	 	March 15 & September 15, commencing March 15, 2012
	 
	 	 
	Price:

	 	100.000% 
	 
	 	 
	Gross Proceeds to Issuer

(before expenses):

	 	$750,000,000 
	 
	 	 
	Record Dates:

	 	March 1 and September 1
	 
	 	 
	Call Schedule:

	 	100% plus a “make-whole premium” prior to September 15, 2016
	 

	 	September 15, 2016: 104.188%
	 

	 	September 15, 2017: 102.792%
	 

	 	September 15, 2018: 101.396%
	 

	 	September 15, 2019: 100.000%
	 

	 	and thereafter
	 
	 	 
	Equity Clawback:

	 	35% at 108.375% prior to September 15, 2014
	 
	 	 
	Change of Control:

	 	Investor put at 101%
	 
	 	 
	Make Whole:

	 	T + 50 b.p.
	 
	 	 
	Denominations:

	 	Minimum denominations of $2,000 and integral multiples of
$1,000 in excess thereof
	 
	 	 
	Joint Book-Running Managers:

	 	Citigroup Global Markets Inc.

Merrill Lynch, Pierce, Fenner & Smith Incorporated

BNP Paribas Securities Corp.

Credit Agricole Securities (USA) LLC
	 
	 	 
	Co-Managers:

	 	Morgan Stanley & Co. LLC

Rabo Securities USA, Inc.

RBS Securities Inc.
	 
	 	 
	Trade Date:

	 	September 16, 2011
	 
	 	 
	Settlement Date (T + 11):

	 	October 3, 2011
	 
	 	 
	Registration Rights:

	 	None
	 
	 	 
	Distribution:

	 	144A and Regulation S

2

 

	 	 	 	 	 

	CUSIP/ISIN:

	 	144A Notes:
	 	Reg. S Notes:
	 

	 	CUSIP: 81211K AR1
	 	CUSIP: U81193 AJ0
	 

	 	ISIN: US81211KAR14
	 	ISIN: USU81193AJ09

This communication is intended for the sole use of the person to whom it is provided by the sender.

These securities have not been registered under the Securities Act of 1933, as amended, and may
only be sold to qualified institutional buyers pursuant to Rule 144A or pursuant to another
applicable exemption from registration.

The information in this term sheet supplements the Company’s preliminary offering memorandum, dated
September 15, 2011 (the “Preliminary Memorandum”) and supercedes the information in the Preliminary
Memorandum to the extent inconsistent with the information in the Preliminary Memorandum. This
term sheet is qualified in its entirety by reference to the Preliminary Memorandum. Terms used
herein but not defined herein shall have the respective meanings as set forth in the Preliminary
Memorandum.

A securities rating is not a recommendation to buy, sell or hold securities and may be subject to
revision or withdrawal at any time.

ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND
SHOULD BE DISREGARDED. SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT
OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER ELECTRONIC SYSTEM.

3

 

SCHEDULE III

Additional Written Information

None

 

 

SCHEDULE IV

List of Acquired Guarantors

Auto-C, LLC

JDI CEE Holdings, Inc.

Diversey Puerto Rico, Inc.

Diversey Shareholdings, Inc.

Professional Shareholdings, Inc.

The Butcher Company

JWP Investments, Inc.

JWPR Corporation

JD Polymer, LLC

 

 

EXHIBIT A

Form of Joinder Agreement

[•], 2011

Citigroup Global Markets Inc.

Merrill Lynch, Pierce, Fenner & Smith

               Incorporated

As Representatives of the Initial Purchasers

c/o Citigroup Global Markets Inc.

388 Greenwich Street

New York, New York 10013

Reference is hereby made to that purchase agreement (the “Purchase Agreement”) dated September 16,
2011 among the Company, certain Guarantors and the Initial Purchasers relating to the issuance and
sale to the Initial Purchasers of $750,000,000 principal amount of its 8.125% Senior Notes due 2019
and $750,000,000 principal amount of its 8.375% Senior Notes due 2021. Capitalized terms used
herein and not otherwise defined herein shall have the meanings ascribed to such terms in the
Purchase Agreement.

In connection with the Acquisition, the undersigned have guaranteed the Notes. This Joinder
Agreement is being executed and delivered by the undersigned on the date of the consummation of the
Acquisition, after giving effect to the Acquisition.

1. Joinder. Each of the undersigned hereby acknowledges that it has received a copy of the Purchase
Agreement and acknowledges and agrees with the Initial Purchasers that by its execution and
delivery hereof it shall (i) join and become a party to the Purchase Agreement; (ii) be bound by
all covenants, agreements, representations, warranties and acknowledgements applicable to such
party as set forth in and in accordance with the terms of the Purchase Agreement; and (iii) perform
all obligations and duties as required of it in accordance with the Purchase Agreement. Each of the
undersigned hereby represents and warrants that the representations and warranties set forth in the
Purchase Agreement applicable to such party are true and correct on and as of the date hereof with
the same force and effect as if such representations and warranties had been made on and as of the
date hereof (except that representations and warranties made as of a particular date were true and
correct on and as of such particular date).

2. Counterparts. This Joinder Agreement may be signed in one or more counterparts (which may be
delivered in original form or facsimile or “pdf” file thereof), each of which shall constitute an
original when so executed and all of which together shall constitute one and the same agreement.

3. Amendments. No amendment or waiver of any provision of this Joinder Agreement, nor any consent
or approval to any departure therefrom, shall in any event be effective unless the same shall be in
writing and signed by the parties thereto.

A-1

 

4. Headings. The section headings used herein are for convenience only and shall not affect the
construction hereof.

5. APPLICABLE LAW. THIS JOINDER AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH,
THE LAWS OF THE STATE OF NEW YORK.

A-2

 

IN WITNESS WHEREOF, each of the undersigned has caused this Joinder Agreement to be duly executed
and delivered in New York, New York, by its proper and duly authorized officer as of the date set
forth above.

Auto-C, LLC

JDI CEE Holdings, Inc.

Diversey Puerto Rico, Inc.

Diversey Shareholdings, Inc.

Professional Shareholdings, Inc.

The Butcher Company

JWP Investments, Inc.

JWPR Corporation

JD Polymer, LLC

	 	 	 	 	 
	 	 	 
	 	By:  	
 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 

 

 

The foregoing Joinder Agreement is hereby confirmed and accepted by the Initial Purchasers as of
the date first above written.

The foregoing Agreement is hereby

confirmed and accepted as of the

date first above written.

Citigroup Global Markets Inc.

Merrill Lynch, Pierce, Fenner & Smith

               Incorporated

For themselves and the other several

Initial Purchasers named in

Schedule I to the foregoing Agreement.

Citigroup Global Markets Inc.

	 	 	 	 	 
	 	 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 

	 	 	 	 	 
	 	Merrill Lynch, Pierce, Fenner & Smith

               Incorporated

 	 

	 	 	 	 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 

 

 

EXHIBIT B-1

Form of Opinion of Simpson Thacher & Bartlett LLP

B-1

 

EXHIBIT B-2

Form of 10b-5 Letter of Simpson Thacher & Bartlett LLP

B-2

 

EXHIBIT C

Form of Opinion of General Counsel of Sealed Air Corporation

C-1

 

EXHIBIT D

Form of Opinion of General Counsel of Diversey Holdings, Inc.

D-1exhibit101.htm

Exhibit 10.1

 

CONFIDENTIAL TREATMENT REQUESTED

 

[***] – CONFIDENTIAL PORTIONS OF THIS AGREEMENT WHICH HAVE BEEN REDACTED ARE MARKED WITH BRACKETS (“[***]”).  THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION.

 

 

SETTLEMENT AGREEMENT AND MUTUAL RELEASE

 

THIS IS AN AGREEMENT between Medtronic, Inc. (“Medtronic”), a Minnesota corporation with its principal place of business at 710 Medtronic Parkway, Minneapolis, Minnesota  55432, Salient Surgical Technologies, Inc. (“Salient”), a Delaware corporation with its principal place of business at 180 International Drive, Portsmouth, New Hampshire 03801, and Bovie Medical Corporation (“Bovie”), a Delaware corporation with its principal place of business at 734 Walt Whitman Road, Melville, New York  11747 (the “Agreement”).  Medtronic and Salient are collectively referred to hereinafter as “Plaintiffs”, and Medtronic, Salient, and
Bovie are collectively referred to hereinafter as the “Parties”.

 

WHEREAS Medtronic is the owner of United States Patent No. 7,364,579 titled “Fluid-Assisted Electrosurgical Device” (“the ‘579 Patent”);

 

WHEREAS Salient is an exclusive, world-wide licensee of the ‘579 Patent, pursuant to agreement between Medtronic and Salient;

 

WHEREAS the Parties have been involved in a litigation concerning Bovie’s alleged infringement of the ‘579 patent in a case styled as Medtronic, Inc. & Salient Surgical Technologies, Inc. v. Bovie Medical Corporation, Case No. 10-494 (SLR), pending before the United States District Court for the District of Delaware (the “Delaware Action”).

 

WHEREAS Bovie filed Counterclaims against Plaintiffs in the Delaware Action;

 

WHEREAS the Parties desire to settle and resolve all claims pending in the Delaware Action between and among each other;

 

WHEREAS concurrently with the execution of this Settlement Agreement, the parties are entering into a stipulation of dismissal in the form attached hereto; and

 

NOW, THEREFORE, in consideration of the mutual covenants, representations, warranties, and other terms and conditions contained herein, the sufficiency of which is hereby acknowledged, the Parties agree as follows:

 

1.           PAYMENT.  In consideration of the promises, covenants and releases granted under this Agreement, Medtronic agrees to pay Bovie the total sum of Seven Hundred Fifty Thousand Dollars (U.S. $750,000) on signing and execution of this Agreement by all Parties (“Effective Date”).

 

  

  

  

[***] = Confidential treatment requested for redacted portion; redacted portion has been filed separately with the Securities and Exchange Commission.

 

1.1           The payment of US $750,000 shall be made within one (1) business day of the Effective Date by wire transfer to the following account:

 

RBC Bank, 4221 W. Boy Scout Blvd., Suite 100, Tampa, Florida 33607

[***]

Bovie Medical Corporation, 5115 Ulmerton Road, Clearwater, FL 33760

Tax ID: 11-2644611

2.           BOVIE’S WITHDRAWAL FROM MARKET.  In consideration of the promises, covenants and releases granted in this Agreement, Bovie, its future licensees of its saline-enhanced RF handpiece technology (hereinafter “Future Licensees”), and any current and future divisions, departments, subsidiaries, parents, affiliates, successors, and predecessors of Bovie, agree to cease and refrain from the importation, use, sale, purchase for resale, offer for sale, advertisement, or possession for resale, both within the United States and worldwide of any monopolar and bipolar
saline-enhanced RF handpiece technology (including SEER and BOSS) (hereinafter “Saline-Enhanced RF Device Business”) from and including the Effective Date through and including February 22, 2015 (hereinafter “Withdrawal Period”).

 

2.1           Bovie agrees, on behalf of itself, its Future Licensees, and its current and future divisions, departments, subsidiaries, parents, affiliates, successors, and predecessors that it will not seek to directly or indirectly enter into the Saline-Enhanced RF Device Business within the United States and worldwide through and including February 22, 2015.

 

2.2           Bovie further agrees that commencing promptly after the Effective Date and during the Withdrawal Period, Bovie shall store its entire finished goods inventory of products related to the Saline-Enhanced RF Device Business in a secure, offsite storage facility.  Such finished goods inventory, whether in the U.S. or abroad, shall be placed into the secure, offsite storage upon its receipt from Bovie’s suppliers.  Bovie shall provide Salient with annual written reports during the Withdrawal Period certifying that the stored goods have remained intact within the storage facility.  Furthermore, Salient may request
and Bovie shall provide a copy of the records from the storage facility as substantiation of Bovie’s certifications.  Bovie may elect to destroy and dispose of the stored goods and, if so, Bovie shall provide Salient advance written notice at least thirty (30) days prior to such action, and shall also provide prompt written notice to Salient certifying said destruction and disposal.

 

2.3           Bovie further agrees on behalf of itself, its Future Licensees, and its current and future divisions, departments, subsidiaries, parents, affiliates, successors, and predecessors that it will not knowingly and voluntarily provide assistance to a third party that would allow that third party to enter into the Saline-Enhanced RF Device Business within the United States and worldwide through and including February 22, 2015.

 

  

2

  

[***] = Confidential treatment requested for redacted portion; redacted portion has been filed separately with the Securities and Exchange Commission.

 

3.           BOSTON SCIENTIFIC CORPORATION.  Notwithstanding Section 2 above, Plaintiffs and Bovie agree and acknowledge that Boston Scientific Corporation (hereinafter “BSC”) is a former owner and transferor to Bovie, and a current Bovie licensee, of certain intellectual property and know-how related to the Saline-Enhanced RF Device Business.  Plaintiffs have knowledge of the terms of the licensure to BSC and for all purposes related to this Settlement agreement, BSC shall be excluded from the
meaning of the phrase “Future Licensee, and its current and future divisions, departments, subsidiaries, parents, affiliates, successors, and predecessors”.

 

4.           DISMISSAL OF PENDING LITIGATION.  The parties agree that this Settlement Agreement is expressly contingent upon the payment of $750,000.00 as provided and specified in Section 1 above, the execution of the mutual releases set forth herein and the stipulation of dismissal of the Delaware Action.  Concurrently with the execution of this Agreement, the Parties shall execute the documents in the form attached as Exhibit 1 pursuant to which the Parties agree to dismiss the Delaware Action with prejudice including all claims and counterclaims, and any claim which could have
been had or brought by and between the Parties arising from or connected with the Delaware Action, and the parties acknowledge the release and discharge of each other from any and all such claims.

 

4.1           Notwithstanding the foregoing, each Party intends and agrees that the United States District Court for the District of Delaware shall be the exclusive jurisdiction for the purpose of resolving any claim or controversy arising out of or relating to the terms and conditions of this Agreement, a Party’s performance or failure to perform hereunder, or any other claim or dispute arising out of the Agreement.

 

4.2           Each Party further agrees to waive any objections it may have now or hereafter to the venue of any proceeding filed in the United States District Court for the District of Delaware for the purposes referenced in this Section.  In any such proceeding to enforce the terms of this Agreement, the Court shall award to the prevailing party its reasonable attorneys’ fees and costs incurred.

 

5.           NO ADMISSION OF INFRINGEMENT OR LIABILITY.  This Agreement is entered into in order to compromise and settle disputed claims, without any acquiescence on the part of any Party as to the merit of any patent-infringement claim, defense, affirmative defense, counterclaim, or of liabilities or damages related to any patent rights or otherwise.  Neither this Agreement nor any part thereof, shall be, or used as, an admission of infringement or liability by anyone, at any time, for any purpose.

 

6.           VALIDITY AND ENFORCEABILITY OF PATENTS.

 

6.1           Bovie acknowledges, on behalf of itself, its Future Licensees, and its current and future divisions, departments, subsidiaries, parents, affiliates, successors, and predecessors, the validity and enforceability of U.S. Patent No. 7,364,579 (the “ ‘579 Patent”), and application No. 08/393,082, filed February 22, 1995, now Patent No. 6,063,081; application No. 08/556,784, filed November 2, 1995, now Patent No. 5,897,553; application No. 09/580,228, filed on May 26, 2000, now Patent No. 6,358,248; application No. 09/955,496, filed on September 18, 2001, now Patent No. 6,585,732; application No. 10/411,921, filed on April 11,
2003, now Patent No. 6,764,487; application No. 10/883,178, filed on July 1, 2004, now Patent No. 6,949,098; application No. 11/230,839, filed on September 20, 2005, now Patent No. 7,166,105 (collectively, “the ‘579 Patent’s Related Patents and Patent Applications”), through and including February 22, 2015.  Bovie further agrees, on behalf of itself, its Future Licensees, and its current and future divisions, departments, subsidiaries, parents, affiliates, successors, and predecessors that it will not knowingly and voluntarily participate, or knowingly and voluntarily assist any third party, in any U.S. Patent Office proceeding or District Court litigation to invalidate and/or declare unpatentable any claim of the ‘579 Patent or any of the ‘579 Patent’s Related Patents and Patent Applications, through and including February 22,
2015.

 

  

3

  

[***] = Confidential treatment requested for redacted portion; redacted portion has been filed separately with the Securities and Exchange Commission.

 

6.2           Bovie further acknowledges, on behalf of itself, its Future Licensees, and its current and future divisions, departments, subsidiaries, parents, affiliates, successors, and predecessors, the validity and enforceability of European Patent, EP 0 863726, and divisional application No. 02015008.2, now European Patent No. 1 245 196 (“the EP Related Patent and Patent Application”), through and including February 22, 2015.  Bovie further agrees, on behalf of itself, its Future Licensees, and its current and future divisions, departments, subsidiaries, parents, affiliates, successors, and predecessors that it will not knowingly
and voluntarily participate, or knowingly and voluntarily assist any third party, in any Patent Office proceeding or litigation to invalidate and/or declare unpatentable any claim of European Patent, EP 0 863726, or any EP Related Patent and Patent Application, through and including February 22, 2015.

7.           RELEASES.

 

7.1           In exchange for Bovie’s above agreements, Medtronic and Salient, together with their respective agents, servants, employees, attorneys, predecessors, successors, assigns, parent and parents, subsidiaries and affiliates, and including the owners, shareholders, directors and officers of each of the foregoing (collectively, the “Salient Parties”) forever irrevocably release and discharge Bovie, its agents, servants, employees, attorneys, predecessors, successors, assigns, parent and parents, subsidiaries and affiliates, and including the owners, shareholders, directors and officers of each of the foregoing (collectively, the
“Bovie Parties”) from any and all claims, demands, threats, suits or proceedings that the Salient Parties have or claim to have or may hereafter have or claim to have against any of the Bovie Parties for infringement of either the ‘579 Patent or any of the ‘579 Patent’s Related Patents and Patent Applications, or the European Patent, EP 0 863726, and the EP Related Patent and Patent Application.  The Salient Parties further forever irrevocably release and discharge the Bovie Parties from any and all claims, demands, threats, suits or proceedings that the Salient Parties have or claim to have directly or indirectly related to or arising from the Delaware Action.

 

7.2           In exchange for Medtronic’s and Salient’s above agreements, the Bovie Parties forever irrevocably release and discharge the Salient Parties from any and all claims, demands, threats, suits or proceedings that the Bovie Parties have or claim to have directly or indirectly related to or arising from the Delaware Action.

 

8.           ATTORNEYS’ FEES AND COSTS.  Except as expressly provided in this Agreement, each Party shall bear its own fees, costs, and expenses incurred in the Delaware Action.

 

  

4

  

[***] = Confidential treatment requested for redacted portion; redacted portion has been filed separately with the Securities and Exchange Commission.

 

9.           PRESS RELEASE  Bovie has drafted and will release a press release that is mutually agreeable to the Parties, which announces the settlement and discloses the material terms of the settlement to the extent required by applicable law, in the opinion of Bovie’s securities counsel.  Notwithstanding, Bovie may include language in the press release regarding a future OEM relationship between Bovie and Salient.  A copy of the press release is attached hereto as Exhibit 2.

 

10.           CONFIDENTIAL.  Subject to the public disclosures permitted under paragraph 9, above, each Party shall keep the terms of this Agreement confidential.  Notwithstanding the foregoing, a Party may disclose such information (a) to the extent it is required to do so by applicable law; (b) to its legal counsel; (c) to accountants, banks, financing sources, prospective purchasers, and their advisors; (d) to officers or employees as needed to perform the Agreement; and, (e) in connection with the enforcement of this Agreement or any rights hereunder.

 

11.           NOTICES.  Any notice, request, demand, or other communication required or permitted hereunder shall be in writing, shall reference this Agreement, and shall be deemed to be properly given: (a) when delivered personally; (b) when sent by facsimile, with written confirmation of receipt; (c) when sent by electronic mail (email) with confirmation of delivery; or, (d) one (1) business day after deposit with a nationally recognized overnight courier with written confirmation of receipt.  All notices shall be sent to the addresses set forth below (or to such other address or
person as may be designated by a Party by giving written notice to the other Party pursuant to this Section):

 

If to Medtronic:

 

Medtronic, Inc.

710 Medtronic Parkway

Minneapolis, Minnesota  55432

Attention:                                

[insert email]

If to Salient:

 

Salient Surgical Technologies, Inc.

180 International Drive

Portsmouth, New Hampshire 03801

Attention: Denise C. Lane, Esq., Director of Legal Affairs & I.P.

denise.lane@salientsurgical.com

If to Bovie:

 

Bovie Medical Corporation

5115 Ulmerton Road

Clearwater, Florida 33760

Attention: Leonard Keen, Esq., VP & General Counsel

Leonard.Keen@boviemed.com 

  

5

  

[***] = Confidential treatment requested for redacted portion; redacted portion has been filed separately with the Securities and Exchange Commission.

12.           NONASSIGNABILITY.  This Agreement may not be assigned by either Party without the prior written consent of all other Parties.  Notwithstanding the foregoing, such other Party’s consent shall not be required for any assignment to an entity that succeeds to all or substantially all of the assigning Party’s business or assets relating to this Agreement, whether by sale, merger, operation of law or otherwise.  This Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective permitted successors and
assigns.

 

13.           FURTHER ASSURANCES.  Each Party agrees to take or cause to be taken such further actions and to execute, deliver, and file or cause to be executed, delivered, and filed such further documents and instruments, and to obtain such consents as may be reasonably required or requested in order to effectuate fully the purposes, terms and conditions of this Agreement.

 

14.           APPLICABLE LAW.  This Agreement shall be governed by the laws of the State of Delaware, and all rights and obligations of the Parties to this Agreement, and the interpretation, construction, and enforceability hereof shall also be governed by the laws of the State of Delaware.

 

15.           SEVERABILITY.  If any term or other provision of this Agreement is determined by a court, administrative agency or arbitrator to be invalid, illegal or incapable of being enforced by any rule of law or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to either Party.  Upon such determination that any term or other provision is invalid, illegal or incapable of being
enforced, the Parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner to the end that transactions contemplated hereby are fulfilled to the fullest extent possible.

 

16.           FAILURE OR INDULGENCE NOT WAIVER.  No failure or delay on the part of either Party hereto in the exercise of any right hereunder shall impair such right or be construed to be a waiver of, or acquiescence in, any breach of any representation, warranty or agreement herein, nor shall any single or partial exercise of any such right preclude other or further exercise thereof or of any other right.

 

17.           AMENDMENT.  No change or amendment will be made to this Agreement except by an instrument in writing signed on behalf of each of the Parties to such agreement.

 

18.           CUMULATIVE REMEDIES.  The rights and remedies of the Parties as set forth in this Agreement are not exclusive and are in addition to any other rights and remedies now or hereafter provided by law or at equity.

 

19.           CONSTRUCTION.  This Agreement has been negotiated by the Parties and shall be interpreted fairly in accordance with its terms and without any construction in favor of or against any Party.

 

  

6

  

[***] = Confidential treatment requested for redacted portion; redacted portion has been filed separately with the Securities and Exchange Commission.

 

20.           COUNTERPARTS.  This Agreement may be executed in counterparts, each of which shall be deemed to be an original but all of which shall constitute one and the same agreement.

 

21.           REPRESENTED BY COUNSEL.  Each Party acknowledges that it has been represented by independent counsel of its choice throughout all negotiations which preceded the execution of this Agreement and all other documents to be executed referred to herein (the “Subject Documents”), and that the Subject Documents have been executed after consultation with such independent legal counsel.

 

22.           REPRESENTATION AND WARRANTY OF AUTHORITY.  The Parties hereto, and the individuals executing this document, personally represent and warrant that each has the capacity and authority to execute this Agreement and bind the respective Parties hereto, together with their affiliates, subsidiaries, parents, assignees, and licensees, all of whom are expressly bound by the terms of this Agreement.

 

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be duly executed on the date written below.

Medtronic, Inc.

By:    _________________________                                       

Name: ________________________                                           

Title:   ________________________                                        

Date:   ________________________                                         

Salient Surgical Technologies, Inc.

By:    _________________________                                       

Name: ________________________                                           

Title:   ________________________                                        

Date:   ________________________                                         

Bovie Medical Corporation

By:    _________________________                                       

Name: ________________________                                           

Title:   ________________________                                        

Date:   ________________________                                         

  

7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}]]